Efficacy of PD-1 Inhibitors in Older Non-small Cell Lung Cancer Patients

被引：1
|
作者：
Nakamura, Yukiko [1 ]
Miyazaki, Kazuhito [1 ]
Aiko, Naoto [1 ]
Misumi, Yuki [1 ]
Agemi, Yoko [1 ]
Taniguchi, Yuri [1 ]
Ishi, Mari [1 ]
Shimokawa, Tsuneo [1 ]
Okamoto, Hiroaki [1 ]
Yamanaka, Takeharu [2 ]
机构：
[1] Yokohama Municipal Citizens Hosp, Dept Resp Med, Yokohama, Kanagawa, Japan
[2] Yokohama City Univ, Sch Med, Dept Biostat, Yokohama, Kanagawa, Japan
来源：
ANTICANCER RESEARCH | 2020年 / 40卷 / 02期
关键词：
Older patients; non-small cell lung cancer; immune checkpoint inhibitor; anti PD-1 inhibitor; overall survival; NIVOLUMAB; DOCETAXEL;
D O I：
10.21873/anticanres.14025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background/Aim: We assessed the efficacy of immune checkpoint inhibitors (ICIs) in older patients because of the limited information regarding these patients. Patients and Methods: We retrospectively analyzed 66 consecutive patients >= 70 years old with advanced non-small cell lung cancer (NSCLC). A total of 31 patients received ICIs (ICIs group) and 35 patients received only cytotoxic regimens (No ICIs group). Results: Patients with squamous cell carcinoma who received ICIs had better overall survival (OS) than those who did not (9.7 versus 4.7 months, p=0.027). In multivariate analysis, treatment with ICIs [hazard ratio (HR)=0.54, 95% confidence interval (CI)=0.30-0.98, p=0.044], good performance status (HR=0.30, 95%CI=0.16-0.57, p=0.0003), and histology other than squamous cell carcinoma (HR=0.41, 95%CI=0.19-0.83, p=0.014) were significantly favorable factors for OS. Conclusion: ICIs may be effective for older patients with NSCLC, especially squamous cell carcinoma patients.
引用
收藏
页码：923 / 928
页数：6
相关论文
共 50 条
  • [21] Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer
    Yuichi Ozawa
    Yusuke Amano
    Kei Kanata
    Hirotsugu Hasegwa
    Takashi Matsui
    Takuya Kakutani
    Takafumi Koyauchi
    Masayuki Tanahashi
    Hiroshi Niwa
    Koshi Yokomura
    Takafumi Suda
    Medical Oncology, 2019, 36
  • [22] PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence
    Byeon, Seonggyu
    Cho, Jang Ho
    Jung, Hyun Ae
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER MEDICINE, 2020, 9 (07): : 2352 - 2362
  • [23] Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials
    Peng, Tzu-Rong
    Wu, Ta-Wei
    THORACIC CANCER, 2019, 10 (05) : 1176 - 1181
  • [24] Efficacy and Safety of Neoadjuvant PD-1 Blockade with Sintilimab in Resectable Non-Small Cell Lung Cancer
    Li, N.
    Ying, J.
    Tao, X.
    Zhang, F.
    Zhao, Z.
    Ling, Y.
    Gao, Y.
    Zhao, J.
    Xue, Q.
    Mao, Y.
    Lei, W.
    Wu, N.
    Wang, S.
    Duan, J.
    Gao, Y.
    Wang, Z.
    Sun, N.
    Wang, J.
    Gao, S.
    He, J.
    Zhou, H.
    Wang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S627 - S628
  • [25] Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients
    Mathew, Divij
    Marmarelis, Melina E.
    Foley, Caitlin
    Bauml, Joshua M.
    Ye, Darwin
    Ghinnagow, Reem
    Ngiow, Shin Foong
    Klapholz, Max
    Jun, Soyeong
    Zhang, Zhaojun
    Zorc, Robert
    Davis, Christiana W.
    Diehn, Maximillian
    Giles, Josephine R.
    Huang, Alexander C.
    Hwang, Wei-Ting
    Zhang, Nancy R.
    Schoenfeld, Adam J.
    Carpenter, Erica L.
    Langer, Corey J.
    Wherry, E. John
    Minn, Andy J.
    SCIENCE, 2024, 384 (6702) : 1314 - +
  • [26] Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer
    Rocco, Danilo
    Malapelle, Umberto
    Del Re, Marzia
    Della Gravara, Luigi
    Pepe, Francesco
    Danesi, Romano
    Troncone, Giancarlo
    Gridelli, Cesare
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (02) : 87 - 96
  • [27] Sex difference in the expression of PD-1 of non-small cell lung cancer
    Gu, Yong
    Tang, Ying Y.
    Wan, Jian X.
    Zou, Jian Y.
    Lu, Chuan G.
    Zhu, Hao S.
    Sheng, Si Y.
    Wang, Yan F.
    Liu, Hai Ch.
    Yang, Jia
    Hong, Hai
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [28] Efficacy and Safety of Anti-PD-1 Inhibitors in Elderly Patients with Advanced Non-Small Cell Lung Cancer
    Tanaka, Y.
    Okano, T.
    Kudo, Y.
    Takeuchi, S.
    Makino, Y.
    Shimada, Y.
    Maehara, S.
    Hagiwara, M.
    Kakihana, M.
    Kajiwara, N.
    Ohira, T.
    Ikeda, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S979 - S980
  • [29] Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China
    Sheng, Jiamin
    Li, Hui
    Yu, Xiaoqing
    Yu, Sizhe
    Chen, Kaiyan
    Pan, Guoqiang
    Xie, Mingying
    Li, Na
    Zhou, Zichao
    Fan, Yun
    THORACIC CANCER, 2021, 12 (22) : 3019 - 3031
  • [30] Efficacy of PD-1 inhibitors in patients with metastatic non-small cell lung cancer (NSCLC) with KRAS or EGFR T790M mutations
    Sharma, Nitika
    Stroud, Chipman Robert Geoffrey
    Walker, Paul R.
    Cherukuri, Sulochana Devi
    Muzaffar, Mahvish
    Cherry, Cynthia R.
    Parent, Teresa
    Hardin, Jessica
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345